Loading live market data…
Loading live market data…
Every ratio from the Fundamental Analysis track, computed on a real company and annotated with what the number actually means. Then the three financial statements, so you can do the cash-flow check yourself.
UPL Limited, together with its subsidiaries, manufactures and sells pesticides, insecticides, and micronutrients in India, Brazil, the United States, the United Kingdom, and internationally. It operates through Crop protection, Seeds & Post-Harvest solutions, and Non-Agro segments. The company offers herbicides, fungicides, insecticides, acaricides, seed treatment, adjuvants, bio-solutions, public health products, fumigants, soil and water technologies, agrochemical products, and other agricultural related products under the Winger, Preview, Propose, and Nuvita brand names, as well as ProNutiva, a solution for crop protection. It also provides seeds for vegetables and crops, such as grain sorghum, forage, corn, canola, sunflower, rice, and wheat as well as other crops, including pearl millets, biofumingants, oats, mustards, and alfalfas under the Advanta, Alta Seeds, and Pacific Seeds brand names. In addition, the company offers industrial and specialty chemicals, such as phosphorus, cynation, phosgenation, and acrolein; other non-agricultural related products; post-harvest solutions; farmer education and engagement; environmental solutions; and apiculture services, as well as operates nurture.farm, a digital platform for growers, farming communities, and food systems. It serves input suppliers, distributors, farmers, food wholesalers/traders, food manufacturers, food retailers, consumers, industry associations, media, cooperatives, government, restaurants, agriculture chemical distributors, and non-government organisations. The company exports its products. The company was formerly known as United Phosphorus Limited and changed its name to UPL Limited in October 2013. UPL Limited was founded in 1969 and is based in Mumbai, India.
How the price compares to earnings, assets and cash generation.
You are paying 21.2 years of current profit for each share. The earnings yield is 4.7%.
The market values the company at 1.3× its accounting net worth. High is normal for asset-light businesses and unusual for banks.
This is the only common multiple that accounts for debt — it is what an actual acquirer would look at, because they would inherit the borrowings.
Pays 1.11% of the current price out each year. Remember that yield rises when price falls — check the dividend is covered by cash flow.
Based on the next-year earnings estimate — 11.0× against 21.2× trailing. A forward P/E well below trailing is pricing in an earnings jump; treat the forecast with caution.
You pay 0.8× annual sales. Useful when earnings are depressed or negative and P/E breaks down — but a high multiple needs high margins to justify it.
Returns on capital and margins, the numerical shadow of a moat.
Not available.
Not available.
Keeps ₹6.6 of operating profit from every ₹100 of sales. Compare only against companies in the same industry.
A thin net margin. A modest rise in input costs or interest rates could erase it entirely.
Keeps ₹49.9 of gross profit per ₹100 of sales, before operating costs. A high, stable gross margin is the clearest single sign of pricing power.
Leverage and liquidity. This is where fragility shows up first.
A conservative balance sheet that can absorb a downturn without a crisis.
Not available.
Not available.
Against cash of ₹6634.00 Cr. Net debt is what matters, not gross borrowings.
Not available.
Revenue and earnings momentum, and how the two compare.
Ask where the growth came from: more volume, higher prices, or an acquisition. They are very different in quality.
Not available.
EBITDA of ₹7984.75 Cr and operating cash flow of —.
Not available.
The figures quoted per share, and how much profit is handed back to owners.
₹24.40 of profit earned per share over the last twelve months. Price divided by this is the trailing P/E.
The accounting net worth behind each share is ₹411.01; price-to-book compares the market price with this.
Pays out 25% of profit as dividends and retains the rest. Above roughly 85% leaves little to reinvest and is hard to sustain through a weak year.
Market cap plus net debt — closer to what an acquirer actually pays. Against a market cap of ₹43684.29 Cr.
Nine yes/no tests of profitability, funding and efficiency across the last two years; higher is stronger. A test is dropped only where the data is missing, so the score is out of 9.
NOPAT ÷ invested capital. What the business earns on all its capital, debt and equity — harder to flatter with leverage than ROE.
A company creates value only when ROIC clears its cost of capital (WACC) — judge this figure against the company’s cost of capital, and watch the trend across years.
Five weighted ratios in one bankruptcy early-warning number. Read the zone and, over time, the trend.
In the distress zone — a red flag worth pairing with the debt schedule and cash-flow statement.
Reported figures, most recent year first. All values in rupees.
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | ₹51303.00 Cr | ₹46262.00 Cr | ₹42599.00 Cr | ₹53134.00 Cr |
| Cost of revenue | ₹26215.00 Cr | ₹24526.00 Cr | ₹24767.00 Cr | ₹27621.00 Cr |
| Gross profit | ₹25088.00 Cr | ₹21736.00 Cr | ₹17832.00 Cr | ₹25513.00 Cr |
| Operating expenses | ₹17985.00 Cr | ₹16116.00 Cr | ₹14984.00 Cr | ₹16763.00 Cr |
| Operating income | ₹7103.00 Cr | ₹5620.00 Cr | ₹2848.00 Cr | ₹8750.00 Cr |
| Interest expense | ₹2853.00 Cr | ₹3232.00 Cr | ₹3378.00 Cr | ₹2984.00 Cr |
| Pre-tax income | ₹3157.00 Cr | ₹829.00 Cr | -₹2087.00 Cr | ₹5150.00 Cr |
| Tax | ₹937.00 Cr | ₹9.00 Cr | -₹209.00 Cr | ₹736.00 Cr |
| Net profit | ₹1922.00 Cr | ₹897.00 Cr | -₹1200.00 Cr | ₹3570.00 Cr |